<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610254</url>
  </required_header>
  <id_info>
    <org_study_id>2022-002137-34</org_study_id>
    <nct_id>NCT05610254</nct_id>
  </id_info>
  <brief_title>The Cold Fluids Study</brief_title>
  <official_title>Rapid Infusion of Ringer's Lactate Solution at Different Temperatures and the Effects on Circulation and Perfusion in Healthy Volunteers - a Randomized Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of South West Jutland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simon Fougner Hartmanns Family Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Clinical Biochemistry, Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of South West Jutland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this single center crossover study the aim is to investigate the effect of Ringer's&#xD;
      lactate solution at high and low temperatures on physiological response in healthy adults.18&#xD;
      healthy volunteers will be included. Inclusion criteria is; Age between 18-64. Exclusion&#xD;
      criteria is; Pre-existing medical problems, Pregnancy (validated through a certified&#xD;
      pregnancy test), Body mass index &gt;35 kg/m2, Medication use apart from allergy medication,&#xD;
      contraceptives, or non-steroidal anti-inflammatory drugs.&#xD;
&#xD;
      Participants will be randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C,&#xD;
      59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. Fluids will be&#xD;
      administered through a peripheral vein. After a minimum &quot;washout period&quot; of 24 hours,&#xD;
      subjects are switched to receive infusion at the other aforementioned temperatures.&#xD;
&#xD;
      Primary outcome is&#xD;
&#xD;
        -  The increase in MAP at 15 minutes after infusion of the fluid bolus. Secondary outcome&#xD;
           is&#xD;
&#xD;
        -  Time until return of MAP to baseline value after infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2022</start_date>
  <completion_date type="Actual">December 3, 2022</completion_date>
  <primary_completion_date type="Actual">December 3, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in MAP at 15 minutes after infusion of the fluid bolus.</measure>
    <time_frame>15 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time until return of MAP to baseline value after infusion.</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Cold-Warm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trial day 1: Participants receive Ringer's lactate cold (15°C, 59°F), Trial day 2: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warm-Cold</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trial day 1: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F) Trial day 2: Participants receive Ringer's lactate cold (15°C, 59°F),</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringer's Lactate</intervention_name>
    <description>On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum &quot;washout period&quot; of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.</description>
    <arm_group_label>Cold-Warm</arm_group_label>
    <arm_group_label>Warm-Cold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-64&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing medical problems&#xD;
&#xD;
          -  Pregnancy (validated through a certified pregnancy test)&#xD;
&#xD;
          -  Body mass index &gt;35 kg/m2&#xD;
&#xD;
          -  Medication use apart from allergy medication, contraceptives, or non-steroidal&#xD;
             anti-inflammatory drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>January 27, 2023</last_update_submitted>
  <last_update_submitted_qc>January 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

